A Null NAC Trial for Fatty Liver, and What Happened in the Control Group

N-acetylcysteine is in a lot of medicine cabinets. It is inexpensive, it has an established role in hospital medicine, and it raises glutathione, which makes it an appealing idea for a liver under metabolic stress. A new randomized trial tested it in people with metabolic dysfunction-associated steatotic liver disease, the condition previously called non-alcoholic fatty liver disease, and the result was negative [1].

Photo: Victoria Aleksandrova / Unsplash

The group that did not get NAC also improved on some measures of liver fat, and that result tells you more about fatty liver care than the NAC result does.

What the researchers found

Researchers in Cairo enrolled 60 non-diabetic adults with MASLD and randomly assigned them to one of two arms [1]. Thirty received oral NAC at 2,400 mg per day alongside a lifestyle intervention. Thirty received the lifestyle intervention alone. The trial ran 12 weeks and was open-label, meaning nobody was blinded and there was no placebo.

The primary outcome was serum malondialdehyde, a marker of oxidative stress. There was no significant difference between groups. There was also no significant difference in leptin (a hormone made by fat tissue that helps regulate appetite), fasting insulin, or HOMA-IR, which is the standard calculation for insulin resistance. FibroScan measurements (an ultrasound-based scan of liver fat and stiffness) and the non-invasive steatosis and fibrosis scores did not differ either. Steatosis is fat buildup in the liver, and fibrosis is scarring.

A few secondary findings changed in ways that are easier to explain by chance than by biology. Liver steatosis scores fell significantly in the control group rather than the NAC group. The hepatic steatosis index, a score calculated from liver enzymes and body mass index, improved in both. Triglycerides dropped significantly in the control arm, while HDL cholesterol rose significantly in the NAC arm. Quality of life scores were flat apart from the emotional domain in the NAC group.

The authors' conclusion is plain: three months of high-dose NAC did not improve oxidative stress, insulin resistance, steatosis, or fibrosis in this population. They also reported that it was safe and well tolerated, which is a separate finding.

What other NAC trials in fatty liver have found

If you read only this trial you would conclude NAC does nothing for a fatty liver. The full literature is messier than that, and the disagreement is specifically about the metabolic markers.

A double-blind, placebo-controlled trial published in 2025 randomized 69 MASLD patients to NAC at 600 mg three times daily or placebo for eight weeks [2]. Like the new trial, it found no change in steatosis grade, liver enzymes, malondialdehyde, or lipids. Unlike the new trial, it reported significant improvements in fasting blood glucose, fasting insulin, HOMA-IR, and CRP (a blood marker of inflammation), along with a rise in total glutathione. Two trials, same condition, opposite answers on insulin resistance.

A pilot study in 13 children with obesity and biopsy-confirmed MASLD reported improvements across inflammation, oxidative stress, insulin resistance, liver enzymes, liver fat fraction, and liver stiffness over 16 weeks [3]. A study of thirteen participants is designed to justify a bigger study, and it cannot settle the question on its own.

A fourth trial compared NAC combined with rosuvastatin (a cholesterol-lowering statin) against vitamin E in 90 patients over six months, and the combination arm improved on steatosis and fibrosis [4]. That design cannot show which of the two agents was responsible.

Across the four trials, the results follow a pattern. In adults, the structural liver outcomes mostly do not change. The blood sugar and inflammation markers sometimes do, and they have not changed consistently enough in blinded trials to call it established. Nobody has replicated a benefit on the thing patients care about most, which is the state of the liver over time.

What the control group shows

The control group is the part of this trial I find most useful. Both arms received a lifestyle intervention, and the hepatic steatosis index improved in both of them [1].

The control group in this study received the lifestyle intervention, which is the treatment with the most evidence behind it for this condition. So the question the trial actually answered was narrower than the headline suggests: does adding NAC do anything on top of the dietary and activity changes that are already the foundation of MASLD care. For these outcomes over these 12 weeks, the answer was no.

I see this pattern constantly in the supplements I get asked about. Something gets tested as an addition to the main intervention, comes back null, and then gets discussed as though the underlying approach failed. The opposite interpretation is closer to the truth. A liver that improves in both arms suggests the diet and activity changes had an effect in both arms.

I still use NAC in practice for particular situations, and I am not going to pretend this trial changes nothing. What it changes for me is how I answer when someone asks whether NAC will help their fatty liver specifically. For that question, in adults, the current answer is that it has not been demonstrated, and the useful part of my job is saying so rather than reaching for the pilot study in 13 children.

For contrast, berberine has a more favorable evidence base in this condition. A meta-analysis of 10 randomized trials with 811 NAFLD patients found significant improvements in the liver enzymes ALT, AST, and GGT, and in triglycerides, total cholesterol, LDL, insulin resistance, and BMI, with only mild gastrointestinal side effects and no significant change in HDL [5]. The authors position it as a possible adjunct rather than a replacement, which is the right way to describe both of these compounds.

Sorting out what your NAC is actually for

1. Ask yourself what you are taking it for. NAC has several distinct uses with very different levels of support behind them, and improving liver fat in adults is currently one of the weakest.

2. Count the lifestyle changes as part of the result. In this trial it was the shared foundation under both arms, and both arms improved on one steatosis measure [1].

3. Treat the doses as a description of the trials. These trials used 2,400 mg daily in adults [1], 1,800 mg daily in the blinded trial [2], and 600 to 1,200 mg daily in the pediatric pilot [3]. Those numbers are reported from the trials and are not recommendations, and dosing decisions belong with your own provider.

4. Track a fatty liver with actual measurements. Enzymes, imaging, and elastography (a scan that measures liver stiffness) are how you know whether something is working, because this condition often causes no noticeable symptoms.

5. Tell whoever manages your care what you are taking. NAC was well tolerated in these trials, and that is still true only when the person looking after the rest of your medications knows you are taking it.

A negative trial still gives you information. This one narrowed the question, and it did not change the foundation of MASLD care, which is still diet and activity changes.

References

Primary research located and verified via PubMed.

1. Ramadan AM, El-Wakeel LM, Adel A, Abdel-Wahab M, Fahmy SF. Effect of high dose N-acetyl cysteine supplementation on markers of oxidative stress and insulin resistance in non-diabetic patients with metabolic dysfunction associated steatotic liver disease: a randomized controlled trial. BMC Gastroenterol. 2026;26(1). PMID 42587287. https://doi.org/10.1186/s12876-026-05157-x (digest source article; publisher page redirects to an authentication wall, so the PubMed record was used as the source of record)

2. Sinaeinejad M, Karimi M, Razavizadeh M, et al. Efficacy of N-Acetylcysteine on Liver Function and Metabolic Profiles in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Double-Blind, Randomized Controlled Trial. Addict Health. 2025;17:1667. PMID 41431629. https://doi.org/10.34172/ahj.1667

3. Babu Balagopal P, Kohli R, Uppal V, et al. Effect of N-acetyl cysteine in children with metabolic dysfunction-associated steatotic liver disease: A pilot study. J Pediatr Gastroenterol Nutr. 2024;79(3):652-660. PMID 38973318. https://doi.org/10.1002/jpn3.12312

4. Zakaria AY, Badawi R, Osama H, Abdelrahman MA, El-Kalaawy AM. New Approach Combination-Dosed Therapy for Nonalcoholic Steatohepatitis Versus Vitamin E: A Randomized Controlled Trial. Clin Ther. 2025;47(8):e19-e30. PMID 40480879. https://doi.org/10.1016/j.clinthera.2025.05.006

5. Nie Q, Li M, Huang C, et al. The clinical efficacy and safety of berberine in the treatment of non-alcoholic fatty liver disease: a meta-analysis and systematic review. J Transl Med. 2024;22(1):225. PMID 38429794. https://doi.org/10.1186/s12967-024-05011-2 (held in the Yggdrasil Abstract Library)

A note before you go

This article is educational and is not medical advice. The doses above are reported from published research rather than recommended to you, and a supplement that was well tolerated in a trial population is not automatically safe alongside your own medications. If you have a fatty liver, monitoring is more important than any single supplement decision, because it is how you find out whether anything is working, and both belong with the provider who can see your labs and your imaging. Please talk with them before you start or stop anything.

---

If this resonates with what you're experiencing and you'd like to explore a naturopathic approach, book a consultation with our clinic.